Giving patients a chance, providing hope, is what drives us


On September 5, 2023, Travere Therapeutics announced that Mirum Pharmaceuticals acquired all of Travere’s rights and assets related to Cholbam® and Chenodal®. For more information please visit mirumpharma.com.

Comprehensive Patient Support

Travere Therapeutics has established a comprehensive patient support program to enable a smooth experience for patients, their caregivers and healthcare providers. This program provides services, assistance and resources to help patients understand their diagnosis, manage the insurance process, fill their prescriptions, and initiate treatment. Use the links above for Travere TotalCare and Total Care Hub to access these services for each therapy.